Form 4 for FENC FENNEC PHARMACEUTICALS INC.
Accepted 2024-04-03 00:00:00 ET · period of report 2024-04-01 · accession 0001415889-24-010047 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-04-03 | 2024-04-01 | FENC | Raykov Rosty | CEO, Dir | P - Purchase | $0.00 | +29.2K | 316.6K | +10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common shares | 2024-04-01 | P | A | 29,167 | $0.00 | 316,638 | D | — | — | (F1) Represents release of restriction from shares awarded 3-31-2023. |